RecruitingNot ApplicableNCT05850130

Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients

A Multicenter, 2-cohort Phase II GERCOR Study to Evaluate the Interest of Acupuncture on Oxaliplatin-induced Peripheral Neuropathy in Patients With Gastro-intestinal Solid Tumors Who Discontinued Oxaliplatin-based Chemotherapy (ACUPOX)

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Enrollment

182 participants

Start Date

Nov 22, 2023

Study Type

INTERVENTIONAL

Conditions

Liver Cancer Colorectal, Cancer Gastric Cancer Esophagus Cancer Pancreas Cancer

Summary

ACUPOX is a multicenter, open label, 2-cohort based phase II clinical study evaluating the interest of a standardized protocol of verum acupuncture in treatment of Oxaliplatin-induced peripheral neuropathy in patients with gastro-intestinal solid tumors who discontinued oxaliplatin-containing chemotherapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria10

Patient is included if:
Agree to participate in this study, voluntarily signing a written informed consent form,
Aged ≥ 18 years,
Have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2,
Have histologically or cytologically confirmed gastro-intestinal solid tumors, previously treated with any oxaliplatin-based chemotherapy; a concomitant radio-chemotherapy course is allowed,
Had the last oxaliplatin infusion \> 2 weeks before inclusion,
Present OIPN with a numerical rating score (NRS) ≥ 4/10 at inclusion,
Currently receiving or recently completed chemotherapy (adjuvant, neoadjuvant, or advanced stage). Patients may receive current chemotherapy treatment (e.g., with FOLFIRI, 5-fluorouracil, bevacizumab regimens), excluding platinum salts and taxane-based regimens during the study,
Are able to understand/read French,
Are registered in a national health care system (PUMa - Protection Universelle Maladie included),

Exclusion Criteria10

Patients is excluded if:
Had acupuncture sessions for the prevention of chemotherapy-induced side effects in the last 3 months prior to inclusion,
Had previous and/or current chemotherapy treatments with taxane-based regimens (e.g., the TFOX regimen \[docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil\]),
Have a history of preexisting clinically-significant peripheral neuropathy due to any cause other than chemotherapy (borrelia infection, human immunodeficiency virus infection, hereditary factors, tumor compression, nutritional deprivation, alcohol, diabetes, etc.),
Have a recent history (within 4 weeks prior to start of acupuncture) of abusing alcohol, prescription, or illicit drugs (including cannabinoid), or medical, psychological, or social conditions that may interfere with the patient's compliance with the study intervention, NB: The patient should be informed that drinking alcohol should be avoided while on study.
Have any other condition that, in the opinion of the investigator, is unstable or could jeopardize the safety of the patient and her/his compliance during the study,
Have limb edema of grade 3 (CTCAE v5),
Had phytotherapy within 2 weeks before a week 1-14 intervention,
Are pregnant or breastfeeding,
Are under the tutorship or guardianship of the state or in custody of the justice system.

Interventions

OTHERAcupuncture intervention

6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints. After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist.

OTHERNo acupuncture

The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).